Login to Your Account

Phase III Study of Rituxan in Leukemia Meets its Goal

By Catherine Hollingsworth

Wednesday, October 8, 2008
Genentech Inc. and Biogen Idec Inc. said their investigational leukemia drug Rituxan (rituximab) passed a second Phase III study, meeting its primary goal of improving the period of time before the disease progresses compared to chemotherapy alone. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription